Nurexone Biologic Inc (NRXBF)

$0.50 +0.00 (0.26%)
Market Cap 41.89M
Revenue (ttm) 0.00
Net Income (ttm) -5.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 400
Avg Vol 9,424
Day's Range N/A - N/A
Shares Out 83.16M
Stochastic %K 23%
Beta -0.51
Analysts Strong Buy
Price Target $3.50

Company Profile

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well...

Industry: Biotechnology
Sector: Healthcare
Address:
1 Adelaide Street East, Suite 801, Toronto, Canada
ZacksSCR
ZacksSCR Dec. 1 at 5:30 PM
$NRXBF Advances Toward Breakthrough Treatments https://buff.ly/IOVP92j
0 · Reply
emberlyWagner61
emberlyWagner61 Nov. 19 at 5:17 PM
$NRXBF (NurExone) exosome therapy for CNS injuries — deep tech, high optionality.
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 31 at 5:20 PM
$NRXBF $NRX
0 · Reply
research_WTR
research_WTR Oct. 31 at 5:12 PM
Check out Robert Sassoon's recap from his podcast with Dr. Lior Shaltiel, PhD, CEO of NurExone (OTCQB: $NRXBF) (TSXV: $NRX) (FSE: J90) and the company’s Co-Founder, VP Strategic Development and Active Chairman Yoram Drucker. Those interested can listen to this podcast on all platforms or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=IR_Healt_10312025 $NRXBF $NRX #NurExone #Healthcare #SmallCap #Stocsk #Investing #CapitalMarkets #WTRInsights #Podcast
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 30 at 7:08 PM
$NRXBF $NRX
0 · Reply
research_WTR
research_WTR Oct. 30 at 4:18 PM
WTR Healthcare Happenings: NurExone Biologic (OTCQB: $NRXBF) (TSXV: $NRX) (FSE: J90)’s ExoTherapy – Reversing the Irreversible 🔹 Breakthrough science: CEO Dr. Lior Shaltiel and Founder Yoram Drucker discuss ExoTherapy, a pioneering exosome-based platform designed to regenerate damaged neurons after spinal cord and optic nerve injuries. 🔹 Transformative results: Preclinical data show up to 100% functional recovery in animal models using siRNA-loaded exosomes. 🔹 Scalable innovation: Their cell-free, off-the-shelf therapy could redefine central nervous system repair. 🔹 Growth catalysts: U.S. manufacturing arm ExoTop set to generate revenue in 2026, with regulatory milestones and plans to uplist to a U.S. exchange. Listen now on all major platforms or our website! Podcast Platforms: https://pod.link/1693448305 Website: https://www.watertowerresearch.com/media-detail/2691/Media #NurExone $NRX $NRXBF #Biotech #HealthcareHappenings #ExosomeTherapy #Neuroscience #RegenerativeMedicine #SpinalCordInjury #CNSRepair #siRNA
0 · Reply
ZacksSCR
ZacksSCR Oct. 27 at 1:41 PM
$NRXBF CEO Chat with Dr. Lior Shaltiel, CEO of NurExone Biologic Inc. https://buff.ly/X9rBUam
0 · Reply
ZacksSCR
ZacksSCR Oct. 13 at 3:17 PM
$NRXBF Treatment Restores Sight https://buff.ly/wmUU6iF
0 · Reply
OptionJunkie36
OptionJunkie36 Sep. 19 at 12:45 PM
$NRXBF hello all. Please excuse the silly questions. I'm a newb here regard this stock. Heard about it on Israeli broadcasted news. But my question is about human trails. Looks like that are just about to start that. Did I get that right?
0 · Reply
ZacksSCR
ZacksSCR Sep. 10 at 3:24 PM
$NRXBF $NRX.TSX Gets Patent for Exciting Cell Technology https://buff.ly/qJQqBwX
0 · Reply
Latest News on NRXBF
No data available.
ZacksSCR
ZacksSCR Dec. 1 at 5:30 PM
$NRXBF Advances Toward Breakthrough Treatments https://buff.ly/IOVP92j
0 · Reply
emberlyWagner61
emberlyWagner61 Nov. 19 at 5:17 PM
$NRXBF (NurExone) exosome therapy for CNS injuries — deep tech, high optionality.
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 31 at 5:20 PM
$NRXBF $NRX
0 · Reply
research_WTR
research_WTR Oct. 31 at 5:12 PM
Check out Robert Sassoon's recap from his podcast with Dr. Lior Shaltiel, PhD, CEO of NurExone (OTCQB: $NRXBF) (TSXV: $NRX) (FSE: J90) and the company’s Co-Founder, VP Strategic Development and Active Chairman Yoram Drucker. Those interested can listen to this podcast on all platforms or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=IR_Healt_10312025 $NRXBF $NRX #NurExone #Healthcare #SmallCap #Stocsk #Investing #CapitalMarkets #WTRInsights #Podcast
0 · Reply
TimRegan_WTR
TimRegan_WTR Oct. 30 at 7:08 PM
$NRXBF $NRX
0 · Reply
research_WTR
research_WTR Oct. 30 at 4:18 PM
WTR Healthcare Happenings: NurExone Biologic (OTCQB: $NRXBF) (TSXV: $NRX) (FSE: J90)’s ExoTherapy – Reversing the Irreversible 🔹 Breakthrough science: CEO Dr. Lior Shaltiel and Founder Yoram Drucker discuss ExoTherapy, a pioneering exosome-based platform designed to regenerate damaged neurons after spinal cord and optic nerve injuries. 🔹 Transformative results: Preclinical data show up to 100% functional recovery in animal models using siRNA-loaded exosomes. 🔹 Scalable innovation: Their cell-free, off-the-shelf therapy could redefine central nervous system repair. 🔹 Growth catalysts: U.S. manufacturing arm ExoTop set to generate revenue in 2026, with regulatory milestones and plans to uplist to a U.S. exchange. Listen now on all major platforms or our website! Podcast Platforms: https://pod.link/1693448305 Website: https://www.watertowerresearch.com/media-detail/2691/Media #NurExone $NRX $NRXBF #Biotech #HealthcareHappenings #ExosomeTherapy #Neuroscience #RegenerativeMedicine #SpinalCordInjury #CNSRepair #siRNA
0 · Reply
ZacksSCR
ZacksSCR Oct. 27 at 1:41 PM
$NRXBF CEO Chat with Dr. Lior Shaltiel, CEO of NurExone Biologic Inc. https://buff.ly/X9rBUam
0 · Reply
ZacksSCR
ZacksSCR Oct. 13 at 3:17 PM
$NRXBF Treatment Restores Sight https://buff.ly/wmUU6iF
0 · Reply
OptionJunkie36
OptionJunkie36 Sep. 19 at 12:45 PM
$NRXBF hello all. Please excuse the silly questions. I'm a newb here regard this stock. Heard about it on Israeli broadcasted news. But my question is about human trails. Looks like that are just about to start that. Did I get that right?
0 · Reply
ZacksSCR
ZacksSCR Sep. 10 at 3:24 PM
$NRXBF $NRX.TSX Gets Patent for Exciting Cell Technology https://buff.ly/qJQqBwX
0 · Reply
BioAmerica
BioAmerica Aug. 21 at 10:51 AM
$NRXBF $XBI $IBB This is some interesting results. Anyone looking for an early stage biotech should look at NRXBF. A ways to go, but this could be very interesting in the years to come. Do your own DD and make sure this fits you investment profile.
0 · Reply
ZacksSCR
ZacksSCR Aug. 11 at 3:21 PM
$NRXBF $NRX.TSX Treatment Shows Remarkable Treatment Properties https://buff.ly/5ZUxNcF
0 · Reply
Northern_Lightz
Northern_Lightz Aug. 11 at 2:48 PM
NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard $NRXBF https://www.globenewswire.com/news-release/2025/08/08/3130357/0/en/NurExone-s-Exosomes-Show-Stronger-Healing-Potential-Than-Industry-Standard.html
0 · Reply
FRCresearch
FRCresearch Jul. 21 at 11:15 PM
$NRXBF Disseminated on behalf of NurExone Biologic Inc. (TSXV: NRX / OTCQB: NRXBF / FSE: J90). Update: @NBiologic’s ExoPTEN showed strong preclinical results, improving motor function in spinal cord injury models. Read our analyst note on NurExone’s ExoPTEN preclinical success: https://www.researchfrc.com/content/analyst-ideas/post/302/top-picks-snapshot-tech-mining-movers
0 · Reply
Northern_Lightz
Northern_Lightz Jul. 10 at 5:37 PM
$NRXBF: Test Results Show Spinal Injury Recovery https://pdfhost.io/v/eKEMku7LuY_NRXBF-_Test_Results_Show_Spinal_Injury_Recovery
0 · Reply
ZacksSCR
ZacksSCR Jul. 9 at 8:38 PM
$NRXBF Treatment Restores Mobility to Spinal Injury Patients https://buff.ly/WG5yt3m
0 · Reply
Northern_Lightz
Northern_Lightz Jul. 9 at 5:18 PM
New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model $NRXBF https://www.globenewswire.com/news-release/2025/07/08/3112213/0/en/New-ExoPTEN-Preclinical-Study-Indicates-Significant-Improvement-in-Walking-Quality-in-Spinal-Cord-Injury-Model.html
0 · Reply
Northern_Lightz
Northern_Lightz Jun. 20 at 12:29 PM
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update $NRXBF https://www.globenewswire.com/news-release/2025/06/20/3102535/0/en/NurExone-Advances-U-S-Growth-Strategy-with-Acceptance-into-Prestigious-ARMI-HealthTech-Hub-Accelerator-and-Provides-Corporate-Update.html
0 · Reply
Mark_Venture
Mark_Venture Jun. 7 at 1:51 AM
$NGENF So, for anyone curious about what research is happening for COMPLETE SCI, $NRXBF is the only one I know of that's making progress in that area, so I've bought 3k shares of it for now. I'm thinking NurExone, followed up with NervGen's treatment might be the way complete SCI can be repaired.
1 · Reply
Mark_Venture
Mark_Venture Jun. 7 at 1:44 AM
$NRXBF I'm thinking NurExone to start the repair of complete SCI, followed by $NGENF to continue it.
1 · Reply
ZacksSCR
ZacksSCR Jun. 2 at 2:32 PM
$NRXBF Makes Significant Announcement https://buff.ly/Hg5xmqI
0 · Reply
ZacksSCR
ZacksSCR May. 27 at 5:26 PM
$NRXBF In Great Position for Exciting Year https://buff.ly/otDPjvG
0 · Reply